STOCK TITAN

Ocugen (OCGN) Financials

OCGN NASDAQ
FY2025 annual
Revenue $4.4M +8.8% YoY
Net Income -$67.8M n/m YoY
Free Cash Flow -$57.1M n/m YoY
Operating Cash Flow -$57.0M n/m YoY
Market Cap $250.8M as of Nov 18, 2026
Price / Sales 56.8x on $4.4M revenue, FY2025
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OCGN SEC filings page.

Ocugen, Inc. (OCGN) reported $4.4M in revenue for fiscal year 2025, up 8.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI OCGN FY2025

Ocugen remains a development-stage business: modest revenue sits beside persistent losses, heavy research spending, and a balance sheet now carrying negative equity.

FY2025 operating cash flow was -$57.0M against only $185K of capital spending, so the cash deficit was overwhelmingly operational rather than reinvestment-driven. With free cash flow at -$57.1M, cash generation confirms that reported earnings still reflect a business consuming cash before expansion spending.

Revenue increased 8.8% in FY2025, yet net loss reached $67.8M, so the modest top-line recovery did not translate into narrower losses. R&D rose 23.7% while interest expense rose 654.1%, pointing to heavier development and financing costs behind the earnings deterioration.

Assets fell 47.2% even as liabilities rose 5.4%, a balance-sheet shift toward less asset backing for obligations. Equity stood at -$12.2M and the current ratio was 1.1x, leaving little reported current-asset cushion relative to near-term liabilities; the liquidity measure was 3.9 months of the latest annual operating outflow.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 43 / 100
Financial Health Score 43/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Ocugen, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
16

Ocugen, Inc. held $18.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $57.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Ocugen, Inc. scores 16/100 among other emerging companies.

Dilution
52

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Ocugen, Inc. scores 52/100 on it among other emerging companies.

R&D Intensity
80

Ocugen, Inc. spent $39.8M on research and development in fiscal year 2025, which was 59.0% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Ocugen, Inc. scores 80/100 among other emerging companies.

Revenue Progress
25

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Ocugen, Inc. scores 25/100 on it among other emerging companies.

Burn Trend
51

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Ocugen, Inc. scores 51/100 on it among other emerging companies.

Balance Sheet
36

Ocugen, Inc.'s cash, cash equivalents and investments came to $18.6M at the end of fiscal year 2025, against $55.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Ocugen, Inc. scores 36/100 among other emerging companies.

Altman Z-Score Distress
-15.06

Ocugen, Inc. scores -15.06, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $408.1M against total assets of $43.5M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
2/8

Ocugen, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.

Earnings Quality No Cash Backing
N/A

Ocugen, Inc. reported a net loss of $67.8M while operations used $57.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Ocugen, Inc. reported an operating loss of $62.9M against $5.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$2.0M
YoY+11.4%
QoQ+31.1%

Ocugen, Inc. generated $2.0M in revenue in Q3 2026. This represents an increase of 11.4% from the same quarter a year earlier. Against the prior quarter it is up 31.1%.

EBITDA
-$17.3M
YoYn/m
QoQn/m

Ocugen, Inc.'s EBITDA was -$17.3M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$3.6M
YoYn/m
QoQn/m

Ocugen, Inc. reported a net loss of $3.6M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.01
YoYn/m
QoQn/m

Ocugen, Inc. earned -$0.01 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$15.9M
YoYn/m
QoQn/m

Ocugen, Inc. recorded an outflow of $15.9M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$24.6M
YoY-25.1%
QoQ-75.4%
5Y CAGR-25.5%
10Y CAGR-4.2%

Ocugen, Inc. held $24.6M in cash against $1.7M in long-term debt as of Q3 2026, with $118.9M of liabilities due within a year.

Shares Outstanding
339M
YoY+8.6%
QoQ+0.1%
5Y CAGR+11.2%

Ocugen, Inc. had 339M shares outstanding in Q3 2026. This represents an increase of 8.6% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$12.5M
YoY+12.1%
QoQ+16.9%

Ocugen, Inc. invested $12.5M in research and development in Q3 2026. This represents an increase of 12.1% from the same quarter a year earlier. Against the prior quarter it is up 16.9%.

Capital Expenditures
$149K
YoY+63.7%
QoQ+609.5%
5Y CAGR-7.7%

Ocugen, Inc. invested $149K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 63.7% from the same quarter a year earlier. Against the prior quarter it is up 609.5%.

Share Buybacks

Not reported for Q3 2026.

OCGN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OCGN quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$2.0M+11.4%$1.5M+8.4%$1.5M+3.5%N/A$1.8M+54.2%$1.4M+20.3%$1.5M+46.1%$764K-45.8%
R&D Expenses$12.5M+12.1%$10.7M+27.2%$11.3M+18.1%N/A$11.1M+37.5%$8.4M-5.6%$9.5M+39.6%$8.3M+6.6%
SG&A Expenses$7.2M-12.4%$7.2M+7.0%$8.1M+25.8%N/A$8.2M+31.0%$6.8M-12.0%$6.5M+0.8%$6.3M+22.5%
Operating Income-$17.8Mn/m-$16.4Mn/m-$17.8Mn/mN/A-$17.6Mn/m-$13.8Mn/m-$14.5Mn/m-$13.8Mn/m
EBITDA-$17.3Mn/m-$15.8Mn/m-$17.2Mn/mN/A-$17.0M-$13.2M-$13.9MN/A
Interest Expense$3.1M+135.2%$4.5M+248.3%$1.3M+5.0%N/A$1.3M+4431.0%$1.3M$1.3MN/A
Net Income-$3.6Mn/m-$24.9Mn/m-$19.2Mn/mN/A-$20.1Mn/m-$14.7Mn/m-$15.3Mn/m-$13.9Mn/m
EPS (Basic)-$0.01n/m-$0.07n/m-$0.06n/mN/A-$0.07-$0.05n/m-$0.05n/mN/A
EPS (Diluted)-$0.01n/m-$0.07n/m-$0.06n/mN/A-$0.07-$0.05n/m-$0.05n/mN/A
Diluted Shares (Avg)339M+11.6%339M+16.0%328M+12.2%N/A304M292M+13.5%292M+13.5%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

OCGN Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OCGN quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$108.1M+87.6%$124.2M+131.8%$56.9M-11.7%$43.5M-47.2%$57.6M-7.0%$53.6M+32.2%$64.5M+24.5%$82.4M+27.7%
Current Assets$91.4M+142.9%$106.7M+224.5%$38.6M-12.3%$24.3M-60.5%$37.6M-7.5%$32.9M+76.6%$44.0M+46.6%$61.7M+43.5%
Cash & Equivalents$24.6M-25.1%$100.1M+270.4%$31.9M-15.6%$18.6M-68.4%$32.9M-15.7%$27.0M+72.1%$37.8M+43.3%$58.8M+49.1%
Short-Term Investments$59.6Mn/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$125.7M+132.6%$140.8M+178.5%$51.1M+5.3%$55.7M+5.4%$54.1M+153.7%$50.5M+114.0%$48.5M+125.4%$52.8M+120.2%
Current Liabilities$118.9M+484.0%$133.1M+639.8%$20.7M+22.6%$23.0M+6.7%$20.4M+29.2%$18.0M+0.1%$16.9M+5.2%$21.6M+26.3%
Non-Current Liabilities$6.8M-79.7%$7.7M-76.4%$30.4M-4.0%$32.6M+4.5%$33.7M+507.9%$32.6M+476.9%$31.7M+477.4%$31.2M+352.9%
Long-Term Debt$1.7M-93.9%$1.7M-93.8%$24.2M-12.6%$27.5M+0.7%$28.4M+1707.8%$28.0M+1705.7%$27.7M+1704.9%$27.3M+876.6%
Total Equity-$17.7M-600.5%-$16.6M-642.5%$5.8M-63.5%-$12.2M-141.1%$3.5M-91.3%$3.1M-82.0%$15.9M-47.4%$29.6M-27.0%
Retained Earnings-$455.7Mn/m-$452.1Mn/m-$427.2Mn/m-$408.1Mn/m-$390.4Mn/m-$370.3Mn/m-$355.6Mn/m-$340.2Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

OCGN Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OCGN quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$15.7Mn/m-$12.2Mn/m-$21.8Mn/m-$14.0Mn/m-$12.9Mn/m-$10.7Mn/m-$19.4Mn/m-$10.4Mn/m
Depreciation & Amortization$500K-16.7%$600K0.0%$600K0.0%N/A$600K$600K$600KN/A
Stock-Based Compensation$2.0M-1.1%$1.8M-0.7%$3.4M+80.3%N/A$2.0M+4.4%$1.8M-2.8%$1.9M+7.0%N/A
Capital Expenditures$149K+63.7%$21K-51.2%$6K-62.5%$35K+169.2%$91K-82.1%$43K-91.6%$16K-99.3%$13K-99.5%
Free Cash Flow-$15.9Mn/m-$12.2Mn/m-$21.8Mn/mN/A-$13.0Mn/m-$10.8Mn/m-$19.4Mn/m-$10.4Mn/m
Investing Cash Flow-$59.8Mn/m-$21Kn/m-$6Kn/m-$35Kn/m-$86Kn/m-$88Kn/m-$102Kn/m-$13Kn/m
Financing Cash Flow$161K-99.1%$80.4M+131650.8%$35.0Mn/m$2K-100.0%$18.5M-46.8%$61K+35.6%-$1.2Mn/m$30.2M+188475.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

OCGN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OCGN quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Margin-909.9%-1105.1%-1163.7%N/A-1006.0%-1004.7%-979.1%-1811.5%
Net Margin-184.4%-1671.8%-1250.9%N/A-1144.5%-1073.5%-1036.5%-1816.8%
Return on EquityN/AN/A-330.4%-233.9ppN/A-567.5%-535.6pp-482.9%-392.7pp-96.5%-57.1pp-46.8%-19.8pp
Return on Assets-3.3%+31.5pp-20.0%+7.5pp-33.7%-9.9ppN/A-34.8%-13.9pp-27.5%+10.2pp-23.8%-0.8pp-16.8%+0.2pp
Current Ratio0.77-1.1x0.80-1.0x1.86-0.7x1.06-1.8x1.85-0.7x1.83+0.8x2.60+0.7x2.86+0.3x
Debt-to-EquityN/AN/A4.17+2.4xN/A8.04+8.0x9.18+9.1x1.74+1.7x0.92+0.9x
Liabilities-to-EquityN/AN/A8.80+5.8xN/A15.30+14.8x16.56+15.2x3.05+2.3x1.78+1.2x
Asset Turnover0.020.0x0.010.0x0.030.0xN/A0.030.0x0.030.0x0.020.0x0.010.0x
FCF Margin-814.4%-821.2%-1422.0%N/A-742.4%-784.6%-1308.1%-1358.2%

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$12.2M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Ocugen, Inc. OCGN FY2025 $4.4M -$67.8M N/A $250.8M 43/100
Prelude Therapeutics Incorporated PRLD FY2025 $12.1M -$99.5M N/A $264.1M 73/100
Allogene Therapeutics, Inc. ALLO FY2025 $0 -$190.9M N/A $241.1M —
Fulcrum Therapeutics, Inc. FULC FY2025 $0 -$74.9M N/A $284.1M —
Inovio Pharmaceuticals, Inc. INO FY2025 $65K -$84.9M N/A $316.5M —
Protalix BioTherapeutics, Inc. PLX FY2025 $52.7M -$6.6M -12.5% $254.6M 41/100

Frequently Asked Questions

Ocugen, Inc. (OCGN) reported $4.4M in total revenue for fiscal year 2025. This represents a 8.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Ocugen, Inc. (OCGN) revenue grew by 8.8% year-over-year, from $4.1M to $4.4M in fiscal year 2025.

No, Ocugen, Inc. (OCGN) reported a net loss of $67.8M in fiscal year 2025.

Ocugen, Inc. (OCGN) had EBITDA of -$60.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Ocugen, Inc. (OCGN) had $18.6M in cash and equivalents against $27.5M in long-term debt.

Ocugen, Inc. (OCGN) recorded an outflow of $57.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Ocugen, Inc. (OCGN) recorded an outflow of $57.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Ocugen, Inc. (OCGN) had $43.5M in total assets as of fiscal year 2025, including both current and long-term assets.

Ocugen, Inc. (OCGN) invested $185K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Ocugen, Inc. (OCGN) invested $39.8M in research and development during fiscal year 2025.

Ocugen, Inc. (OCGN) had 328M shares outstanding as of fiscal year 2025.

Ocugen, Inc. (OCGN) had a current ratio of 1.06 as of fiscal year 2025, which is considered adequate.

Ocugen, Inc. (OCGN) had a return on assets of -155.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Ocugen, Inc. (OCGN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $250.8M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Ocugen, Inc. (OCGN) trades at 56.8x sales, its market capitalization divided by $4.4M revenue, FY2025. The market capitalization is $250.8M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Ocugen, Inc. (OCGN) held $18.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $57.0M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Ocugen, Inc. (OCGN) has negative shareholder equity of -$12.2M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Ocugen, Inc. (OCGN) has an Altman Z-Score of -15.06, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Ocugen, Inc. (OCGN) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Ocugen, Inc. (OCGN) reported a net loss of $67.8M while operations used $57.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Ocugen, Inc. (OCGN) reported an operating loss of $62.9M against $5.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Ocugen, Inc. (OCGN) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top